KDT-3594 ( DrugBank: KDT-3594 )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease4

6. Parkinson disease


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2031210089
15/05/202113/05/2021A clinical study of KDT-3594 in Japanese patients with early Parkinson's disease.A phase II clinical study of KDT-3594 in Japanese patients with early Parkinson's disease. Parkinson's diseaseOral and titrated doses of KDT-3594Shimizu YoshitakaNULLComplete>= 20age old< 80age oldBoth6Phase 2Japan
2NCT04867551
(ClinicalTrials.gov)
May 15, 202127/4/2021A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's DiseaseA Phase II Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's DiseaseParkinson DiseaseDrug: KDT-3594Kissei Pharmaceutical Co., Ltd.NULLCompleted20 Years79 YearsAll7Phase 2Japan
3NCT03845387
(ClinicalTrials.gov)
February 26, 201915/2/2019A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.Parkinson DiseaseDrug: KDT-3594;Drug: PramipexoleKissei Pharmaceutical Co., Ltd.NULLCompleted20 Years79 YearsAll74Phase 2Japan
4NCT03068481
(ClinicalTrials.gov)
February 20, 201726/2/2017Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseA Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's DiseaseParkinson DiseaseDrug: KDT-3594;Drug: PlaceboKissei Pharmaceutical Co., Ltd.NULLCompleted20 Years74 YearsAll36Phase 1Japan